Rich has served as a member of PhaseBio’s board of directors since February 2019. He has nearly 30 years of experience in financial strategy and investment fund management in the life sciences industry, and currently serves as managing partner of HSMR Advisors, an investment fund focused on the biotechnology industry. Prior to joining HSMR Advisors in 2004, Rich was partner at Cooper Hill Partners. Earlier in his career, he was a biotechnology analyst at Hambrecht & Quist, Merrill Lynch and Oppenheimer, and has previously served as a director at Pharmacyclics, Response Genetics and Celldex Therapeutics. Rich holds a bachelor’s degree from Harvard University and is a Chartered Financial Analyst.